Recent Company News

• 05:22 PM ET Jan 27, 2026
  

  Radiopharm Theranostics reports Q2 net cash from / (used in) operating activities (A$13.4M) - Appendix 4C ($4.92, 0.00)

• 09:43 AM ET Jan 21, 2026
  

  Transcript Intelligence: Radiopharm Theranostics at Emerging Growth Conference ($5.01, 0.00)

• 04:35 PM ET Jan 11, 2026
  

  Radiopharm Theranostics increases stake in Radiopharm Ventures to 87.5% from 75% (A$0.03, 0.00)

• 09:31 AM ET Dec 17, 2025
  

  StreetAccount Summary - US Syndicate recap for 17-Dec

• 08:36 AM ET Dec 17, 2025
  

  StreetAccount Summary - US Initial Syndicate recap for 17-Dec

• 05:17 PM ET Dec 16, 2025
  

  Radiopharm Theranostics files $50M mixed shelf; enters into sales agreement for up to $22.4M of ADSs with Leerink Partners - F-3 ($5.99, 0.00)

• 09:16 AM ET Dec 16, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:28 AM ET Dec 16, 2025
  

  StreetAccount Summary - US Pre-market trading

• 07:29 PM ET Dec 15, 2025
  

  Transcript Intelligence: Radiopharm Theranostics RAD 101 Phase 2 Clinical Trial Call ($10.63, 0.00)

• 06:13 PM ET Dec 15, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market